[go: nahoru, domu]

Jump to content

GlobalStem

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vlcko (talk | contribs) at 19:25, 17 November 2006 (Page setup). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
GlobalStem, Inc.
Company typePrivate
IndustryBiotechnology
Founded2006
HeadquartersRockville, Maryland, 39 05' 48 N and 77 07'47 W
Key people
Jonathan Auerbach,
Number of employees
6 (2006)
Websitehttp://www.GlobalStem.com/

GlobalStem, Inc. is a biotechnology company based in Rockville, Maryland.

Trophogen was formed by two molecular endocrinologists who spent numerous years as academians at NIH and the University of Maryland, Baltimore before striking out on their own to launch their first entrepreneurial endeavor. Operating with staff of five scientists, their research is focused on the development of high affinity glycoprotein hormone and related growth factor analogs (FSH, LH and TSH) for targeted therapy and imaging of ovarian, breast, prostate, testicular and thyroid cancers as well as for human and animal infertility.


is a provider of high-quality laboratory products and services for the stem cell research community. The company is based in Rockville, Maryland and serves an international base of academic, private industry and government customers. The company was founded in 2006 by a team of experienced stem cell researchers who desired to bring to market better quality and more standardized research tools. GlobalStem is engaged in collaborative and strategic partnerships with a number of major companies in the stem cell research field, and is a leading resource center to foster the advancement of human embryonic stem cell research.

Lead Product Candidates
1.- LH- and FSH superagonist- radionuclide or –toxin for the targeted therapy of ovarian cancer
2.- LH superagonist- radionuclide or –toxin for the targeted therapy of breast and prostate cancer
3.- TSH superagonist- radionuclide or –toxin for the targeted therapy of thyroid cancer
4.- TSH superagonist for enhancing 131I diagnostic scanning and treatment of thyroid cancer
3.- Labeled TSH superagonist imaging agent for thyroid cancer
6.- FSH and LH superagonist for the treatment of human and animal infertility
7.- VEGF superagonist for therapeutic targeting of tumor vasculature, vascular imaging and as a media supplement for endothelial and stem cell proliferation/differentiation